FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition for treating breast cancer. Composition contains fulvestrant at concentration of 30–110 mg/ml, a pharmaceutically acceptable solvent at concentration of 280–1400 mg/ml, a solubilizer at concentration of 100–200 mg/ml, an antioxidant at concentration of 1–5 mg/ml, where the antioxidant is thioctic acid. Preferably, the solvent is a mixture comprising propylene glycol, benzyl alcohol and glycofurol. Pharmaceutical composition of fulvestrant can be packaged in a container, such as a bottle or syringe. Method of treating breast cancer, comprising administering a composition of fulvestrant, is also described.
EFFECT: fulvestrant composition according to the invention is characterized by increased stability.
28 cl, 3 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ABIRATERONE PRODRUGS | 2020 |
|
RU2822219C2 |
| PHARMACEUTICAL COMPOSITIONS FOR PROLONGED RELEASE OF SEBACOYL-DINALBUPHINE ESTER | 2016 |
|
RU2718900C2 |
| LYOPHILISED PREPARATION OF CYTOTOXIC DIPEPTIDES | 2012 |
|
RU2597154C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
| PHARMACEUTICAL COMPOSITION OF TAXOIDS | 2011 |
|
RU2603833C2 |
| FULVESTRANT COMPOSITIONS | 2001 |
|
RU2263507C2 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| PHARMACEUTICAL COMPOSITIONS FOR INHALATIONS CONTAINING NITROPROSTON | 2017 |
|
RU2662099C1 |
| PHARMACEUTICAL COMPOSITIONS IN LIQUID DOSAGE FORM FOR TREATMENT OF CEREBROVASCULAR DISORDERS AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2582961C1 |
| VETERINARY COMPOSITIONS AND THEIR USE FOR CONTROL OF IRON DEFICIENCY IN NON-HUMAN MAMMALS | 2019 |
|
RU2812291C2 |
